Structure Therapeutics - A Strong Bet For An Oral GLP-1 Approval Before 2030 (NASDAQ:GPCR)
· seekingalpha.com
Structure Therapeutics (GPCR): oral GLP-1 aleniglipron shows 16.2% weight loss; Phase 3 underway, cash runway strong. Read the latest analysis on the stock here.
If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and ...